Authors: Jahns-Streubel, G Braess, J Schoch, C Fonatsch, C Haase, D Binder, C Wormann, B Buchner, T Hiddemann, W

Citation: G. Jahns-streubel et al., Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF, LEUKEMIA, 15(3), 2001, pp. 377-384

Authors: Braess, J Jahns-Streubel, G Schoch, C Haase, D Haferlach, T Fiegl, M Voss, S Kern, W Schleyer, E Hiddemann, W

Citation: J. Braess et al., Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroupsin acute myeloid leukaemia, BR J HAEM, 113(4), 2001, pp. 975-982

Authors: Braess, J Jahns-Streubel, G Voss, S Kern, W Keye, S Schleyer, E Hiddemann, W

Citation: J. Braess et al., The endogenous leukemic proliferation rate and cytosine arabinoside pharmacodynamics are major determinants for therapeutic success in acute myeloid leukemia, INT J CL PH, 38(3), 2000, pp. 150-151

Authors: Braess, J Voss, S Jahns-Streubel, G Schoch, C Haferlach, T Kern, W Keye, S Schleyer, E Hiddemann, W

Citation: J. Braess et al., The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with ahigh proliferative activity, BR J HAEM, 110(1), 2000, pp. 170-179

Authors: Braess, J Wegendt, C Jahns-Streubel, G Kern, W Keye, S Unterhalt, M Schleyer, E Hiddemann, W

Citation: J. Braess et al., Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine, BR J HAEM, 109(2), 2000, pp. 388-395

Authors: Sachse, C Jahns-Streubel, G Henkel, E

Citation: C. Sachse et al., First clinical evaluation of the CELL-DYN (R) 3200 haematology analyser, CLIN LAB H, 20(6), 1998, pp. 333-340